

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 24, 2008

Electronic Signature for A. Jacqueline Wizeman, Ph.D.: /A. Jacqueline Wizeman/

Docket No.: EISN-018CP
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kenichi Chiba *et al.*

Application No.: 10/657,910

Confirmation No.: 5169

Filed: September 9, 2003

Art Unit: 1625

For: MACROCYCLIC COMPOUNDS USEFUL
AS PHARMACEUTICALS

Examiner: Oh, Taylor V.

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicants note that the cited documents were cited in a September 10, 2008 Office Action in related application number 10/507,067. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

The Examiner is also advised that the following commonly owned patents and applications contain subject matter that may be related to the present application.

Application No.	Filing Date	Attorney Docket No.	Status
10/507,067	11-10-2004	EISN-018US	Pending
12/180,408	07-25-2008	EISN-003	Pending
12/180,423	07-25-2008	EISN-012	Pending

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PAIR. However, if the Examiner has difficulty obtaining papers from that source he is invited to call the undersigned who will be happy to supply them.

This Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 12-0080, under Order No. EISN-018CP.

Dated: October 24, 2008

Respectfully submitted,

Electronic signature: /A. Jacqueline Wizeman/
A. Jacqueline Wizeman, Ph.D.
Registration No.: 62,307
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant